Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Total Liabilities (2022 - 2025)

Entrada Therapeutics has reported Total Liabilities over the past 4 years, most recently at $71.2 million for Q4 2025.

  • Quarterly results put Total Liabilities at $71.2 million for Q4 2025, down 27.04% from a year ago — trailing twelve months through Dec 2025 was $71.2 million (down 27.04% YoY), and the annual figure for FY2025 was $71.2 million, down 27.04%.
  • Total Liabilities for Q4 2025 was $71.2 million at Entrada Therapeutics, down from $72.2 million in the prior quarter.
  • Over the last five years, Total Liabilities for TRDA hit a ceiling of $287.1 million in Q2 2023 and a floor of $39.3 million in Q1 2022.
  • Median Total Liabilities over the past 4 years was $84.9 million (2024), compared with a mean of $129.0 million.
  • Biggest five-year swings in Total Liabilities: surged 619.88% in 2023 and later tumbled 71.34% in 2025.
  • Entrada Therapeutics' Total Liabilities stood at $39.5 million in 2022, then soared by 474.23% to $226.8 million in 2023, then tumbled by 56.95% to $97.6 million in 2024, then dropped by 27.04% to $71.2 million in 2025.
  • The last three reported values for Total Liabilities were $71.2 million (Q4 2025), $72.2 million (Q3 2025), and $69.3 million (Q2 2025) per Business Quant data.